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Macrophage infectivity potentiator (Mip) and Mip-like proteins are virulence factors in a
wide range of pathogens including Legionella pneumophila. These proteins belong to the
FK506 binding protein (FKBP) family of peptidyl-prolyl-cis/trans-isomerases (PPIases). In
L. pneumophila, the PPIase activity of Mip is required for invasion of macrophages, trans-
migration through an in vitro lung–epithelial barrier, and full virulence in the guinea pig
infection model. Additionally, Mip is a moonlighting protein that binds to collagen IV in the
extracellular matrix. Here, we describe the development and synthesis of cycloheximide
derivatives with adamantyl moieties as novel FKBP ligands, and analyze their effect on
the viability of L. pneumophila and other bacteria. All compounds efficiently inhibited PPI-
ase activity of the prototypic human FKBP12 as well as Mip with IC50-values as low as
180 nM and 1.7µM, respectively. Five of these derivatives inhibited the growth of L. pneu-
mophila at concentrations of 30–40µM, but exhibited no effect on other tested bacterial
species indicating a specific spectrum of antibacterial activity. The derivatives carrying a
3,5-dimethyladamantan-1-[yl]acetamide substitution (MT_30.32), and a 3-ethyladamantan-
1-[yl]acetamide substitution (MT_30.51) had the strongest effects in PPIase- and liquid
growth assays. MT_30.32 and MT_30.51 were also inhibitory in macrophage infection
studies without being cytotoxic. Accordingly, by applying a combinatorial approach, we
were able to generate novel, hybrid inhibitors consisting of cycloheximide and adaman-
tane, two known FKBP inhibitors that interact with different parts of the PPIase domain,
respectively. Interestingly, despite the proven Mip-inhibitory activity, the viability of a Mip-
deficient strain was affected to the same degree as its wild type. Hence, we also propose
that cycloheximide derivatives with adamantyl moieties are potent PPIase inhibitors with
multiple targets in L. pneumophila.
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INTRODUCTION
The Gram-negative bacterium Legionella pneumophila is the
causative agent of Legionnaires’ disease, a severe community
acquired, and atypical pneumonia with mortality rates up to 5–
30% despite appropriate antibiotic treatment (Fields et al., 2002).
The virulence factor macrophage infectivity potentiator (Mip) of
L. pneumophila is important for the establishment of the intra-
cellular infection (Cianciotto et al., 1989; Cianciotto and Fields,
1992). It is a homodimeric lipoprotein that is localized on the
surface of the bacteria (Helbig et al., 2001; Köhler et al., 2003).
The dimerization occurs via its N-terminus that is followed by
a long and flexible α-helix, and a C-terminal peptidyl-prolyl-
cis/trans-isomerase (PPIase) domain that catalyzes the cis/trans
interconversion of Xaa-Pro peptide bonds (Lang et al., 1987; Fis-
cher et al., 1989; Riboldi-Tunnicliffe et al., 2001). Mip belongs
to the family of FK506 binding proteins (FKBP), and its PPIase
domain is structurally highly similar to human FKBP12. Accord-
ingly, both proteins interact with the natural inhibitors FK506 and
rapamycin in a similar way (Ceymann et al., 2008).
Mip was shown to be the first virulence associated PPIase (Fis-
cher et al., 1992). Mip-negative mutants are delayed in the onset
of the intracellular replication cycle in several host cell types like
macrophage cell lines, alveolar macrophages, blood monocytes,
lung epithelial cells, and protozoan hosts (Cianciotto et al., 1989,
1990, 1995; Cianciotto and Fields, 1992; Wintermeyer et al., 1995).
Beyond monocellular hosts, Mip contributes to bacterial replica-
tion as well as dissemination within the lung tissue, and subsequent
spread to the spleen in guinea pigs (Engleberg et al., 1989; Cian-
ciotto et al., 1990; Cianciotto and Fields, 1992). This process could
be simulated, and the contribution of Mip confirmed in in vitro
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transmigration assays. Furthermore, degradation assays with 35S-
labeled ECM proteins support the hypothesis of a concerted action
of Mip and proteolytic enzymes of either host or bacterial origin
(Wagner et al., 2007).
Mip exerts part of its virulence associated functions in the lung
by moonlighting as it can interact with collagen IV (Wagner et al.,
2007). This interaction is mediated by the PPIase domain, which
binds to a distinct 13-mer sequence within the non-collagenous
domain (NC1) of the α1 isomer of collagen IV, and promotes
transmigration of the bacteria across barriers constituted by colla-
gen containing extracellular matrices (ECM) or lung epithelial cell
lines (Wagner et al., 2007; Ünal et al., 2011). Hence, attenuation of
Mip-deficient mutant bacteria in the guinea pig infection model
is partly influenced by the moonlighting properties of Mip that
facilitates adhesion to the ECM followed by efficient colonization
and destruction of lung tissue.
Currently, moonlighting proteins that contribute to bacterial
infections arise as interesting new therapeutic targets (Hender-
son and Martin, 2014). Since homologs of Mip are also present
in other intracellularly replicating and persisting pathogens like
Trypanosoma cruzi, Coxiella burnetii, Neisseria gonorrhoeae, and
several members of the genus Chlamydia, it is suggested that
moonlighting Mip and Mip-related PPIases are potential targets
for novel antimicrobials (Lundemose et al., 1993; Mo et al., 1995;
Moro et al., 1995; Rockey et al., 1996; Leuzzi et al., 2005). The char-
acterized inhibitors rapamycin and FK506 are not suitable antibi-
otics, because they also interact with human FKBPs. Complexes
of human FKBP12 and FK506 dock to the protein phosphatase
calcineurin, thereby blocking T cell proliferation via the NFAT
pathway (Liu et al., 1992). Moreover, the FKBP12-rapamycin com-
plex inhibits an essential Ser/Thr protein kinase called mammalian
target of rapamycin (mTOR), thereby influencing IL-2 receptor
signal transduction (Boytim et al., 2000). As a result, both drugs
have immunosuppressive properties that find clinical use mainly
during organ transplantations (Gaali et al., 2011).
The search for non-immunosuppressive FKBP inhibitors has
resulted in the discovery, or de novo design of several non-
macrolide structures (Ünal and Steinert, 2014). Among those is
the natural compound cycloheximide of Streptomyces griseus that
was identified by screening a compound library. While cyclo-
heximide is an efficient inhibitor of eukaryotic protein synthe-
sis, its imide-substituted derivatives, such as cycloheximide N -
ethylethanoate (Figure 1A) or N -(N ′,N ′-dimethylcarboxamido-
methyl)-cycloheximide (DM-CHX), are devoid of this side effect,
and potently inhibit FKBPs (Christner et al., 1999; Edlich et al.,
2006; Norville et al., 2011). In contrast, adamantane and its deriva-
tives (Figure 1B) were identified and produced in a custom tailored
process by computational predictions based on the structure of the
FKBP12-FK506 complex (Babine et al., 1995). Interestingly, these
two substance classes seem to interact with FKBPs in different
ways. While cycloheximide N -ethylethanoate primarily binds to
the vicinity of the enzymatic cleft, adamantane and its derivatives
can replace the pipecolinic acid moiety of FK506 making close
contact to several conserved amino acids in the PPIase pocket
(Babine et al., 1995; Norville et al., 2011). The aims of the present
study were the synthesis of novel Mip ligands by the combina-
tion of both substance classes and the evaluation of their PPIase
FIGURE 1 | Non-macrolide FKBP-inihibitors. Shown are the two main
building blocks of the novel FKBP inhibitors presented in this study.
(A) Cycloheximide N -ethylethanoate is a non-toxic derivative of the natural
compound cycloheximide, an inhibitor of eukaryotic translation.
(B) Adamantane was identified by structure based computational modeling
as an appropriate scaffold that can replace the pipecolinic acid moiety in
FK506, which interacts with the PPIase active cleft of FKBPs. Adamantane
and substituents of it were fused to N -(carboxymethyl)cycloheximide in
order to produce novel cycloheximide derivatives (see alsoTable 1).
inhibitory action as well as their spectrum of antibacterial activity
and potential as suppressors of Legionella-infection.
MATERIALS AND METHODS
MATERIALS FOR CHEMICAL SYNTHESIS
All chemicals,unless otherwise noted,were purchased from Sigma-
Aldrich and were of reagent grade. Trifluoroacetic acid (TFA)
was obtained from Merck. FK506 and cyclosporine A (CsA)
were obtained from LC Laboratories. Acetonitrile (ACN) HPLC
gradient grade was purchased from Fisher Scientific.
INSTRUMENTATION
The preparative HPLC Sykam contained two S1021 pumps, a
controller S2001, an Abimed 118 UV/VIS detector and reverse
phase columns Phenomenex Gemini-NX 250× 21.2 C18, and a
Phenomenex Jupiter Proteo 90A AX 250× 21.2. Solvent A: H2O.
Solvent B: ACN. The purity of the final products was determined
using a Dionex analytical HPLC unit coupled with a photo-
diode array detector and a Vydac reverse phase column (C18
5µm, 4.6 mm× 250 mm column) coupled with a Surveyor MSQ
(Thermo Finnigan) mass spectrometer. The same solvent system
used for preparative HPLC was used for analytical HPLC. Dem-
ineralized water was additionally purified with a Millipore water
purification system.
CHEMICAL SYNTHESIS
N-(carboxymethyl)cycloheximide
To a solution of cycloheximide (500 mg; 1.78 mmol) in 15 ml
of DMF was added tert-butylbromo acetate (369µl; 2.5 mmol)
and anhydrous K2CO3 (442 mg; 3.2 mmol), and the solution was
stirred overnight at room temperature. After evaporation of the
solvent, the resulting residue was dissolved in ethyl acetate and
filtered following evaporation of ethyl acetate.
The entire crude product N -[methyl-(tert-butyloxycarbonyl)]
cycloheximide was dissolved in 20 ml of CH2Cl2, and 4 ml of a
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2.2M zinc (II)-chloride diethyl etherate solution (freshly prepared)
was added and stirred at room temperature for 4 h. The mixture
was transferred into a separatory funnel and washed with a sat-
urated aqueous ETDA solution (2 ml× 10 ml). The layers were
separated and the organic phase was washed an additional time
with 10 ml of a saturated aqueous NaCl solution. The organic layer
was separated, dried over Na2SO4, and the solvent was evaporated.
The crude product was used without further purification. The
crude N -(carboxymethyl)cycloheximide was achieved with a yield
of 479 mg (79% relating to applied amount of cycloheximide).
[M+H]+ calc.= 340.2, [M+H]+ found= 340.4.
MT_30.32
N -(carboxymethyl)cycloheximide (10.0 mg; 29.5µmol), PyBOP
(16.0 mg; 29.5µmol), and N -ethyldiisopropylamine (15.0µl;
74.5µmol) were dissolved in 4 ml DMF and pre-incubated for
5 min. 3,5-dimethyl-1-adamantamine hydrochloride (12.0 mg;
59.0µmol) was added and the mixture was stirred for 1 h at
room temperature. The solvent was evaporated and the crude
product was purified via preparative HPLC using a RP C18 col-
umn (Phenomenex Gemini-NX, 250× 21.2) with a linear gradi-
ent of 30–80% ACN in 40 min and a flow rate of 17.0 ml/min.
The product was achieved with a yield of 6.7 mg (45.5%).
[M+H]+ calc.= 501.3, [M+H]+ found= 501.5.
MT_30.51
N -(carboxymethyl)cycloheximide (10.0 mg; 29.5µmol), PyBOP
(16.0 mg; 29.5µmol), and N -ethyldiisopropylamine (15.0µl;
74.5µmol) were dissolved in 4 ml DMF and pre-incubated
for 5 min. (3-ethyl-1-adamantyl)amine hydrochloride (12.8 mg;
59.0µmol) was added and the mixture was stirred for 1 h at
room temperature. The solvent was evaporated and the crude
product was purified via preparative HPLC using a RP C18 col-
umn (Phenomenex Gemini-NX, 250× 21.2) with a linear gradi-
ent of 20–60% ACN in 30 min and a flow rate of 17.0 ml/min.
The product was achieved with a yield of 8.6 mg (58.5%).
[M+H]+ calc.= 501.3, [M+H]+ found= 501.4.
MT_30.38
N -(carboxymethyl)cycloheximide (10.0 mg; 29.5µmol), PyBOP
(16.0 mg; 29.5µmol), and N -ethyldiisopropylamine (10.4µl;
59.0µmol) were dissolved in 4 ml DMF and pre-incubated for
5 min. 3-Amino-1-adamantol (9.8 mg; 59.0µmol) was added
and the mixture was stirred for 1 h at room temperature. The
solvent was evaporated and the crude product was purified
via preparative HPLC using a RP C18 column (Phenomenex
Gemini-NX, 250× 21.2) with a linear gradient of 30–80% ACN
in 40 min and a flow rate of 17.0 ml/min. The product was
achieved with a yield of 7.2 mg (50.0%). [M+H]+ calc.= 489.3,
[M+H]+ found= 489.3.
MT_30.79
N -(carboxymethyl)cycloheximide (10.0 mg; 29.5µmol), PyBOP
(16.0 mg; 29.5µmol), and N -ethyldiisopropylamine (10.4µl;
59.0µmol) were dissolved in 4 ml DMF and pre-incubated for
5 min. 3-amino-5,7-dimethyl-adamant-1-ol (11.5 mg; 59.0µmol)
was added and the mixture was stirred for 1 h at room temperature.
The solvent was evaporated and the crude product was purified
via preparative HPLC using a RP C18 column (Phenomenex
Gemini-NX, 250× 21.2) with a linear gradient of 30–80% ACN
in 40 min and a flow rate of 17.0 ml/min. The product was
achieved with a yield of 6.3 mg (41.4%). [M+H]+ calc.= 517.4,
[M+H]+ found= 517.3.
MT_30.3
N -(carboxymethyl)cycloheximide (10.0 mg; 29.5µmol), PyBOP
(16.0 mg; 29.5µmol), and N -ethyldiisopropylamine (10.4µl;
59.0µmol) were dissolved in 4 ml DMF and pre-incubated
for 5 min. Tert-butylamine (6.2µl; 59.0µmol) was added and
the mixture was stirred for 1 h at room temperature. The
solvent was evaporated and the crude product was purified
via preparative HPLC using a RP C18 column (Phenomenex
Gemini-NX, 250× 21.2) with a linear gradient of 30–80% ACN
in 40 min and a flow rate of 17.0 ml/min. The product was
achieved with a yield of 5.9 mg (50.8%). [M+H]+ calc.= 395.2,
[M+H]+ found= 395.3.
MT_30.9
N -(carboxymethyl)cycloheximide (10.0 mg; 29.5µmol), PyBOP
(16.0 mg; 29.5µmol), and N-ethyldiisopropylamine (10.4µl;
59.0µmol) were dissolved in 4 ml DMF and pre-incubated for
5 min. Tert-butylmethylamine (7.0 mg; 59.0µmol) was added
and the mixture was stirred for 1 h at room temperature. The
solvent was evaporated and the crude product was purified
via preparative HPLC using a RP C18 column (Phenomenex
Gemini-NX, 250× 21.2) with a linear gradient of 30–80% ACN
in 40 min and a flow rate of 17.0 ml/min. The product was
achieved with a yield of 9.2 mg (76.7%). [M+H]+ calc.= 409.2,
[M+H]+ found= 409.4.
MT_30.8
N -(carboxymethyl)cycloheximide (10.0 mg; 29.5µmol), PyBOP
(16.0 mg; 29.5µmol), and N -ethyldiisopropylamine (10.4µl;
59.0µmol) were dissolved in 4 ml DMF and pre-incubated
for 5 min. 1-aminoadamantan (9.0 mg; 59.0µmol) was added
and the mixture was stirred for 1 h at room temperature. The
solvent was evaporated and the crude product was purified
via preparative HPLC using a RP C18 column (Phenomenex
Gemini-NX, 250× 21.2) with a linear gradient of 30–80% ACN
in 40 min and a flow rate of 17.0 ml/min. The product was
achieved with a yield of 8.7 mg (62.6%). [M+H]+ calc.= 473.3,
[M+H]+ found= 473.5.
MT_30.92
(S)-2-methyl-CBS-oxazaborolidine (1.2 mg; 21.2µmol) and a 1M
solution of BH3 in THF (22.0µml; 21.2µmol) were dissolved
in 5 ml of anhydrous THF and stirred for 15 min. This solution
was added slowly within 30 min to a stirred solution of MT_30.8
(10.0 mg; 21.2µmol) in 10 ml anhydrous THF at 0°C. The stirring
is maintained for 40 min. Thereafter, 10 ml of methanol was added
and the solution was evaporated. The crude product was puri-
fied via preparative HPLC using a RP C12 column (Phenomenex
Gemini-NX, 250× 21.2) with a linear gradient of 30–80% ACN
in 40 min and a flow rate of 17.0 ml/min. The product was
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achieved with a yield of 5.8 mg (58.0%). [M+H]+ calc.= 475.3,
[M+H]+ found= 475.5.
MT_30.93
(R)-2-methyl-CBS-oxazaborolidine (1.2 mg; 21.2µmol) and a
1M solution of BH3 in THF (22.0µml; 21.2µmol) were dis-
solved in 5 ml of anhydrous THF and stirred for 15 min. This
solution was added slowly within 30 min to a stirred solution
of MT_30.8 (10.0 mg; 21.2µmol) in 10 ml anhydrous THF at
0°C. The stirring is maintained for 40 min. Thereafter, 10 ml of
methanol was added and the solution was evaporated. The crude
product was purified via preparative HPLC using a RP C12 col-
umn (Phenomenex Jupiter Proteo 90A AX, 250× 21.2) with a
linear gradient of 30–80% ACN in 40 min and a flow rate of
17.0 ml/min. The product was achieved with a yield of 6.9 mg
(69.1%). [M+H]+ calc.= 475.3, [M+H]+ found= 475.3.
PROTEASE COUPLED PPIase ASSAY
The PPIase activity of Mip or FKBP12 was determined by using
the peptide substrate Succinyl-Ala-Leu-Pro-Phe-4-nitroanilide in
the protease-coupled PPIase assay as described previously (Fischer
et al., 1992). Briefly, 30 nM Mip or 8 nM FKBP12 was preincu-
bated with 40µM peptide substrate in the presence or absence
of various inhibitor concentrations for 4 min at 10°C in 35 mM
HEPES/NaOH buffer (pH 7.8). Then, reaction was started by addi-
tion of 100µg/mL of the isomer specific protease chymotrypsin,
and the release of 4-nitroaniline was monitored by measuring the
absorbance at 390 nm.
DETERMINING THE MINIMAL INHIBITORY CONCENTRATION
The minimal inhibitory concentration (MIC) method was used
to determine the minimal concentration of cycloheximide deriva-
tives that is needed to inhibit the growth of L. pneumophila Corby,
Yersinia pseudotuberculosis, Escherichia coli K12, Staphylococcus
aureus, Pseudomonas aeruginosa PA01, Salmonella enterica subsp.
Enterica, and Klebsiella aerogenes. All bacteria were cultured in LB
(Luria-Bertani) medium except for L. pneumophila, which were
grown in YEB medium (buffered yeast extract broth). All bacterial
species were cultured overnight at 37°C and 200 rpm, and adjusted
to 2× 107 cells/ml with LB or YEB, respectively. One hundred
microliter aliquots of these bacterial suspensions were transferred
to 96 well plates and were mixed with an additional 100µl medium
with and without several cycloheximide derivatives starting at con-
centrations between 10 and 100µM concentrations with 10µM
increments. Bacteria were cultured at 37°C and 180 rpm for 2 days,
and growth was measured at 600 nm in a microplate reader.
IN VITRO ACTIVITY OF CYCLOHEXIMIDE DERIVATIVES IN INFECTED
MACROPHAGES
The human monocyte cell line THP-1 (ACC 16) was pur-
chased from the German Collection of Microorganisms and
Cell Cultures (The Leibniz Institute DSMZ), and maintained in
RPMI supplemented with 10% fetal bovine serum and 2 mM
l-glutamine at 37°C in a 5% CO2-atmosphere. For infection
assays, the monocytes were adjusted to 5× 105 cells/ml in fresh
medium supplemented with 100 nM phorbol-12-myristate-13-
acetate (PMA, Sigma–Aldrich P8139). Two hundred microliters
of this suspension were transferred into the wells of a 96-well
cell culture plate, and the cells were differentiated for 2 days into
macrophage-like cells.
For infection, L. pneumophila Corby was grown over night in
YEB medium to early stationary phase. Bacteria were washed once
with H2Odd (3 min, 6000× g, RT), and adjusted to 106 cfu/ml in
fresh RPMI (infection medium). The medium of differentiated
THP-1 cells was replaced by 100µl of infection medium (MOI
1). After 2 h, extracellular bacteria were removed by washing three
times with pre-warmed PBS. Finally, the cells were covered with
fresh medium containing cycloheximide derivatives at the indi-
cated concentrations. Medium containing only 1% (v/v) ethanol
or 1% (v/v) DMSO was used as control. Uptake of bacteria and
bacterial replication were monitored by lysing the cells after 2 and
24 h after infection, respectively, by adding Triton X-100 at a final
concentration of 0.1% (v/v), and plating out serial dilutions on
BCYE agar plates.
CYTOTOXICITY ASSAY
In order to rule out cytotoxic side effects of the biologically
active cycloheximide derivatives on eukaryotic cells, the viabil-
ity of THP-1 cells was measured using the Alamar Blue reagent
(Biozol, #BZL00726) according to manufacturer’s instructions.
Briefly, THP-1 cells were prepared as described above. Instead of
infecting the cells, they were incubated with 100µM MT_30.32,
or MT_30.51 for 20 h, at which time point Alamar Blue reagent
was added. After another 4 h, cell viability was assessed by mea-
suring fluorescence intensity at 590 nm (excitation 570 nm) using
a Varioskan™ Multimode plate reader (Thermo Scientific).
RESULTS
NOVEL IMIDE SUBSTITUTED CYCLOHEXIMIDE DERIVATIVES POSSESS
IMPROVED FKBP INHIBITORY ACTIVITIES
In the search for novel FKBP inhibitors without immunosup-
pressive side effects, we decided to extend the number of deriv-
atives of the already described imide substituted cycloheximide
compounds (Christner et al., 1999). Of the nine compounds
generated for this study, two (MT_30.3 and MT_30.9) were
produced using tert-butylamine as a substituting functionality,
while the rest carried adamantane based substitutions (Table 1).
The inhibitory activities of these compounds were evaluated
in a protease coupled PPIase assay with the chromogenic pep-
tide substrate Succinyl-Ala-Phe-Pro-Phe-4-nitroanilide using the
human FKBP12 as well as Mip of L. pneumophila. Generally,
all the substances inhibited FKBP12 more efficiently than Mip
except for MT_30.9, which was with IC50-values of 36.1± 4.1
and 31.7± 7.4µM for FKBP12 and Mip, respectively, also the
least efficient inhibitor. Similarly, the most effective inhibitor of
FKBP12, MT_30.32 (IC50 0.18± 0.05µM), had with 1.7± 0.2µM
the lowest IC50-value for Mip. This correlation between FKBP12
and Mip could also be observed for the second and third best
inhibitors MT_30.51 and MT_30.79, respectively. However, in
case of these derivatives, the IC50-values for Mip were about
25-fold higher than for FKBP12, hence, considerably higher
than MT_30.32. The remaining compounds inhibited FKBP12
and Mip in the range of 1–2 and 1.5–34µM, respectively
(Table 1).
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Table 1 | PPIase inhibitory activities of novel cycloheximide derivatives
and their structures.
Compound Structure IC50 (FKBP12) IC50 (Mip)
MT_30.3 2.0±0.1µM 33.8±8.6µM
MT_30.8 0.4±0.04µM 8.5±2.1µM
MT_30.9 36.1±4.1µM 31.7±7.4µM
MT_30.32 0.18±0.05µM 1.7±0.2µM
MT_30.38 1.2±0.1µM 21.8±3.3µM
MT_30.51 0.19±0.06µM 5.6±1.1µM
MT_30.79 0.22±0.02µM 4.9±0.9µM
MT_30.92 1.0±0.1µM 12.6±1.4µM
MT_30.93 0.9±0.05µM 16.3±2.6µM
CYCLOHEXIMIDE DERIVATIVES SPECIFICALLY INHIBIT GROWTH OF L.
PNEUMOPHILA IN LIQUID CULTURE
Since novel cycloheximide derivatives were able to inhibit the PPI-
ase activity of Mip, we went on to evaluate the effect of these
compounds on Legionella growth in liquid culture and during
macrophage infection. For determining the MIC-values of the
derivatives, wild type L. pneumophila and its isogenic ∆mip-
mutant strain were cultured in the presence of the respective
compound at final concentrations ranging from 10 to 100µM. As a
control, the known Mip inhibitor rapamycin was used. Substances
MT_30.9, MT_30.32, and MT_30.51 inhibited the growth of L.
pneumophila completely at a concentration of 30µM, whereas,
MT_30.92 and MT_30.93 started to inhibit at 40µM. In contrast,
the compounds MT_30.3, MT_30.8, MT_30.38, and MT_30.79
had no influence on the viability of wild type L. pneumophila.
Remarkably, no differences could be observed in the spectrum
and range of activity of the inhibitors between the L. pneumophila
wild type and its isogenic mip-deficient mutant. Another inter-
esting observation was that rapamycin also exhibited a growth
inhibitory activity on both strains at a concentration of 40µM or
higher (Table 2).
The strongest inhibitor in the PPIase assay, MT_30.32, was cho-
sen as a representative, and further tested against the clinically
Table 2 | MICs evaluated for L. pneumophila Corby and its isogenic
mip-deficient mutant.
Compound WT ∆mip
Inhibitiona MICb Inhibition MIC
MT_30.3 - - - -
MT_30.8 - - - -
MT_30.9 + 30 + 30
MT_30.32 + 30 + 30
MT_30.38 - - - -
MT_30.51 + 30 + 30
MT_30.79 - - - -
MT_30.92 + 40 + 40
MT_30.93 + 40 + 40
Rapamycin + 40 + 40
a(-): no inhibition of growth at the highest tested concentration of 100µM.
bMinimal inhibitory concentrations are given in µM.
relevant Gram-negative species Y. pseudotuberculosis, P. aerugi-
nosa PA01, S. enterica subsp. enterica, K. aerogenes, and E. coli
K12, as well as the Gram-positive pathogen S. aureus. To our sur-
prise, none of the tested strains were affected in their growth by
MT30_32 indicating that the antibacterial activity of our novel
cycloheximide derivatives is either restricted to a narrow range of
bacterial species or even specific against L. pneumophila (data not
shown).
CYCLOHEXIMIDE DERIVATIVES WITH ADAMANTYL SUBSTITUTION
INHIBIT LEGIONELLA REPLICATION DURING INFECTION
During lung infection, L. pneumophila parasitizes human alveo-
lar macrophages for its replication. Therefore, we tested whether
the strongest inhibitors MT_30.32 and 30.51 were also capable
of inhibiting bacterial replication during infection in differenti-
ated THP-1 macrophages. In accordance with the protease cou-
pled PPIase and MIC assays, both substances suppressed bacterial
replication in THP-1 cells in a concentration dependent manner
starting at 50µM. In contrast, MT_30.9 that also inhibited bac-
terial growth but was about 18-fold less effective than MT_30.32
in the protease coupled PPIase-assay, had no effect on bacterial
replication in THP-1 cells at the highest tested concentration of
100µM (Figure 2A). None of the substances were cytotoxic to the
THP-1 cells (Figure 2B).
DISCUSSION
The increase in antibiotic resistant strains and the spread of
antibiotic resistance among disease causing organisms have put
moonlighting proteins in the spotlight of the search for alter-
native drug targets, because their moonlighting properties are
very often relevant for virulence (Henderson and Martin, 2014).
The primary aim of this study was the design of non-macrolide,
non-immunosuppressive inhibitors of the moonlighting virulence
factor Mip of L. pneumophila. Mip originally was identified as a
virulence factor that is needed during the early time points of
intracellular replication in macrophages and protozoa (Cianciotto
et al., 1989; Cianciotto and Fields, 1992; Fischer et al., 1992). While
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FIGURE 2 | Cycloheximide derivatives differentially inhibit bacterial
replication during infection and are not cytotoxic. (A) All inhibitors were
tested in macrophage infection assays at concentrations ranging from 12.5
to 100µM. The substances were added at the indicated concentrations 2 h
post infection, and the bacterial replication was monitored by determining
the colony forming units/milliliter (cfu/ml) 24 h post infection. The novel
PPIase inhibitors MT_30.32 and MT_30.51 effectively suppressed bacterial
replication during infection of differentiated THP-1 cells in a concentration
dependent manner. The remaining seven derivatives had no effect at the
highest concentration tested as demonstrated by the example MT_30.9,
and were comparable to untreated infections containing only 1% (v/v)
ethanol as the solvent at its final concentration. The graph depicts mean
and SD of two independent experiments performed in duplicate as a
representative of four biological replicates. (B) Differentiated THP-1 cells
were incubated with 100µM MT_30.32 or MT_30.51 for 24 h. After 20 h,
alamar blue was added and cell viability was determined by measuring
fluorescence at 590 nm. The medium of control cells was either free of
additives (untreated) or contained 1% (v/v) EtOH as a solvent control. The
graph shows the mean and SD of two independent experiments performed
in triplicate.
the PPIase activity affects invasion of monocellular cells, but not
intracellular replication, a mutant strain expressing a Mip vari-
ant with very low PPIase activity is attenuated in the guinea pig
infection model (Wintermeyer et al., 1995; Köhler et al., 2003).
In accordance with observations in the animal model, Mip was
shown to bind as a moonlighting protein collagen IV in the ECM
of lung tissue. By doing this, it enables efficient colonization and
dispersal of the bacteria to the spleen of infected animals extending
its functions beyond the infection of monocellular hosts (Wagner
et al., 2007).
Due to the high structural similarity between Mip and human
FKBPs, like FKBP12, the design of Mip specific inhibitors benefits
much from structural data and computational modeling. Until
now two approaches for the design of Mip-specific inhibitors have
been published. First, the moonlighting property was utilized, and
the binding sequence within collagen IV was identified as being
a 13-mer proline-rich peptide (P290) within the NC1-domain of
collagen IV(α1). This peptide was chemically synthesized, and a
computer model of the solution structure of the Mip-P290 com-
plex could be generated following NMR measurements. Predic-
tions based on this computer model allowed the design of a cyclic
variant of P290 that was able to decrease bacterial transmigration
across an in vitro epithelial cell barrier (Ünal et al., 2011).
In a second approach, Juli and coworkers synthesized novel
pipecolic acid derivatives by starting from rapamycin, because
computational analysis of the NMR structure of the Mip-
rapamycin complex shows that rapamycin’s pipecoline moiety is
anchored in the hydrophobic active site of Mip (Ceymann et al.,
2008; Juli et al., 2011). The resulting compounds were found
to inhibit the PPIase activity of Mip with IC50 values as low as
6µM. However, the compounds inhibited the prototypic human
FKBP12 30-fold more efficiently than Mip, indicating low speci-
ficity for bacterial FKBPs (Juli et al., 2011). In a follow-up study,
the inhibitory activities of these derivatives were also confirmed
for BpML1 and Mip-like proteins of the pathogens Yersinia pestis
and Francisella tularensis (Begley et al., 2014).
For the design of novel inhibitors with increased specificity
for Mip, we followed in the present study a new approach, and
combined two previously described FKBP inhibitors by using syn-
thetic chemistry. Of these inhibitors, cycloheximide was identified
by classical functional screens, while adamantane was predicted
by computer modeling, and its derivatives were validated exper-
imentally (Babine et al., 1995; Christner et al., 1999). A general
observation for the novel cycloheximide derivatives presented
in this study was that imide substitution of cycloheximide with
adamantyl derivatives yielded more efficient Mip inhibitors than
substituting with tert-butylamine, since the highest IC50-value was
16.3± 2.6µM for the former group (MT_30.93) compared to
31.7± 7.4µM as the lowest IC50-value for the latter (MT_30.9)
(Table 1).
Cycloheximide-N -ethylethanoate was reported to have an
IC50-value of 6.5± 1µM toward the Mip-like protein of Burk-
holderia pseudomallei (BpML1) (Norville et al., 2011). By using
adamantyl derivatives as substituents, we were able to produce
cycloheximide derivatives with improved IC50-values as low as
1.7± 0.2µM in case of MT_30.32 supporting our combinator-
ial approach. Although the substances were, except for MT_30.9,
more efficient inhibitors of FKBP12, the specificity toward Mip
could also be increased compared to the previously described
pipecolinic acid derivatives as MT_30.32 inhibited FKBP12 only
10-fold better.
Currently, we only can speculate about the binding mode
of MT_30.32 and MT_30.51 to Mip. For cycloheximide-N -
ethylethanoate, an NMR structure of its complex with BpML1
is published (2KO7). This revealed that the cycloheximide deriva-
tive displays a different binding mode than it is reported for FK506
and rapamycin. Rather than in the enzymatic cleft, cycloheximide-
N -ethylethanoate interacts with residues in the close vicinity of
it, and especially two loops outside the core (Norville et al.,
2011). Similarly, a crystal structure of the adamantane derivative,
supradamal, in complex with FKBP35 of Plasmodium vivax exists
(4MGV). Here, the adamantane functionality perfectly fits into the
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FIGURE 3 | Structural alignment of Mip to known PPIase-inhibitor
complexes. Shown are the structural overlays of the surface model of Mip
(1FD9, green) with (A) the PvFKBP35-SAR-complex (4MVG, red) and (B) the
BpML1- cycloheximide N -ethylethanoate complex (2KO7, red). The ligands are
shown as sticks. The overlay in (A) suggests that Mip and PvFKBP35 are
topologically more similar in the hydrophobic cleft, where SAR docks.
Accordingly, a comparable binding mode of MT_30.32 or MT_30.51 to Mip via
their adamantyl moiety can be assumed. The overlay in (B) reveals substantial
topological differences between Mip and BpML1 in the loop region and the
vicinity of the hydrophobic cleft that are reported to interact with
cycloheximide N-ethylethanoate. Hence, the cycloheximide portions of
MT_30.32 and MT_30.51 most probably bind in a different mode to Mip. The
structural alignments were performed using PyMOL Molecular Graphics
System, Version 1.5.0.4 Schrödinger, LLC.
hydrophobic cleft making non-bonded contacts with many con-
served amino acids including Trp77 (Trp162 in Mip), which forms
the base of the PPIase cavity (Harikishore et al., 2013). When these
two structures are taken as reference and used for aligning Mip,
it can be seen that the topological similarities between the PPIase
domains of PvFKBP35 and Mip are higher than BpML1 and Mip
(Figure 3). Due to the higher similarity between PvFKBP35 and
Mip, it can be assumed that the adamantane moieties bind simi-
larly to Mip by occupying the hydrophobic cavity (Figure 3A). In
contrast, Mip and BpML1 differ especially in the region of the loop
that is reported to interact with cycloheximide-N -ethylethanoate.
Mip has a much bulkier topology at this part, which would affect
the binding of cylocheximide inhibitors (Figure 3B). Accordingly,
it would be very interesting for future studies to determine the
binding mode of MT_30.32 or MT_30.51.
Having seen the improvement in Mip inhibitory capacity of the
novel cycloheximide derivatives by achieving lower IC50-values
and higher specificity, we evaluated their antibacterial poten-
tial in liquid growth and infection assays. Of the seven deriva-
tives with adamantyl substitutions, four (MT_30.32, MT_30.51,
MT_30.92, and MT_30.93) were able to inhibit bacterial growth
in liquid culture starting at 30µM (Table 2). Of those four, only
two (MT_30.32 and MT_30.51) inhibited bacterial replication in
macrophages without having cytotoxic side effects.
An interesting finding of our biological screens was that the
inhibitory action of the four adamantyl substituted cycloheximide
derivatives was independent of Mip, since a ∆mip-mutant was
affected by the same compounds to the same extent. This indi-
cates that there are additional drug target(s) than Mip. To our
knowledge, there is no other FKBP in L. pneumophila except the
ribosome associated trigger factor (TF) that contains a central
FKBP domain (Rasch et al., 2014). However, the PPIase activity
of TF is dispensable in many bacteria (Hoffmann et al., 2010).
Hence, it is questionable, whether TF is the additional target of
the biologically active derivatives. Apart from this, the facts that
deletion of mip is not deleterious to the bacteria, but the inhibitors
MT_30.32 and MT_30.51 are, nonetheless, effective during infec-
tion, suggest that some Mip functions might be taken over by
other PPIases. A respective example has recently been described
in E. coli, where deleting the periplasmic parvulin type PPIase
SurA and the chaperone Skp is deleterious at 37°C due to the
defects in the assembly of outer membrane proteins. However,
under heat shock conditions this defect disappears because of
the up-regulation of the periplasmic FKBP-type FkpA (Ge et al.,
2014). Thus, it would be interesting for the future studies to test
whether other Legionella PPIases can also be targeted by MT_30.32
and MT_30.51, or whether there might be alternative Legionella
targets for these compounds. In conclusion, the adamantyl sub-
stituted cycloheximide derivatives presented in this study can be
considered as a novel type of PPIase inhibitors with potential as
antibacterial therapeutics.
ACKNOWLEDGMENTS
This work received financial support from the Deutsche
Forschungsgemeinschaft (DFG) STE 838/8-1.
REFERENCES
Babine, R. E., Bleckman, T. M., Kissinger, C. R., Showalter, R., Pelletier, L. A., Lewis,
C., et al. (1995). Design, synthesis and X-ray crystallographic studies of novel
FKBP-12 ligands. Bioorg. Med. Chem. Lett. 5, 1719–1724. doi:10.1016/0960-
894X(95)00290-A
Begley, D. W., Fox, D., Jenner, D., Juli, C., Pierce, P. G., Abendroth, J., et al. (2014).
A structural biology approach enables the development of antimicrobials tar-
geting bacterial immunophilins. Antimicrob. Agents Chemother. 58, 1458–1467.
doi:10.1128/AAC.01875-13
Boytim, M. L., Lilly, P., Drouvalakis, K., Lyu, S. C., Jung, R., Krensky, A. M., et al.
(2000). A human class II MHC-derived peptide antagonizes phosphatidylinosi-
tol 3-kinase to block IL-2 signaling. J. Clin. Invest. 105, 1447–1453. doi:10.1172/
JCI8139
Ceymann, A., Horstmann, M., Ehses, P., Schweimer, K., Paschke, A.-K., Steinert, M.,
et al. (2008). Solution structure of the Legionella pneumophila Mip-rapamycin
complex. BMC Struct. Biol. 8:17. doi:10.1186/1472-6807-8-17
Christner, C., Wyrwa, R., Marsch, S., Küllertz, G., Thiericke, R., Grabley, S., et al.
(1999). Synthesis and cytotoxic evaluation of cycloheximide derivatives as poten-
tial inhibitors of FKBP12 with neuroregenerative properties. J. Med. Chem. 42,
3615–3622. doi:10.1021/jm991038t
www.frontiersin.org March 2015 | Volume 3 | Article 41 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rasch et al. Cycloheximide derivatives as moonlighting inhibitors
Cianciotto, N. P., Bangsborg, J. M., Eisenstein, B. I., and Engleberg, N. C. (1990).
Identification of mip-like genes in the genus Legionella. Infect. Immun. 58,
2912–2918.
Cianciotto, N. P., Eisenstein, B. I., Mody, C. H., Toews, G. B., and Engleberg,
N. C. (1989). A Legionella pneumophila gene encoding a species-specific sur-
face protein potentiates initiation of intracellular infection. Infect. Immun. 57,
1255–1262.
Cianciotto, N. P., and Fields, B. S. (1992). Legionella pneumophila mip gene poten-
tiates intracellular infection of protozoa and human macrophages. Proc. Natl.
Acad. Sci. U.S.A. 89, 5188–5191. doi:10.1073/pnas.89.11.5188
Cianciotto, N. P., O’Connell, W., Dasch, G. A., and Mallavia, L. P. (1995). Detection
of mip-like sequences and Mip-related proteins within the family Rickettsiaceae.
Curr. Microbiol. 30, 149–153. doi:10.1007/BF00296200
Edlich, F., Weiwad, M., Wildemann, D., Jarczowski, F., Kilka, S., Moutty, M. C., et al.
(2006). The specific FKBP38 inhibitor N-(N’,N’-dimethylcarboxamidomethyl)
cycloheximide has potent neuroprotective and neurotrophic properties in brain
ischemia. J. Biol. Chem. 281, 14961–14970. doi:10.1074/jbc.M600452200
Engleberg, N. C., Carter, C., Weber, D. R., Cianciotto, N. P., and Eisenstein, B. I.
(1989). DNA sequence of mip, a Legionella pneumophila gene associated with
macrophage infectivity. Infect. Immun. 57, 1263–1270.
Fields, B. S., Benson, R. F., and Besser, R. E. (2002). Legionella and Legion-
naires’ disease: 25 years of investigation. Clin. Microbiol. Rev. 15, 506–526.
doi:10.1128/CMR.15.3.506-526.2002
Fischer, G., Bang, H., Ludwig, B., Mann, K., and Hacker, J. (1992). Mip protein
of Legionella pneumophila exhibits peptidyl-prolyl-cis/trans isomerase (PPlase)
activity. Mol. Microbiol. 6, 1375–1383. doi:10.1111/j.1365-2958.1992.tb00858.x
Fischer, G., Wittmann-Liebold, B., Lang, K., Kiefhaber, T., and Schmid, F. X. (1989).
Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical pro-
teins. Nature 337, 476–478. doi:10.1038/337476a0
Gaali, S., Gopalakrishnan, R., Wang, Y., Kozany, C., and Hausch, F. (2011). The
chemical biology of immunophilin ligands. Curr. Med. Chem. 18, 5355–5379.
doi:10.2174/092986711798194342
Ge, X., Lyu, Z.-X., Liu, Y., Wang, R., Zhao, X. S., Fu, X., et al. (2014). Identi-
fication of FkpA as a key quality control factor for the biogenesis of outer
membrane proteins under heat shock conditions. J. Bacteriol. 196, 672–680.
doi:10.1128/JB.01069-13
Harikishore, A., Niang, M., Rajan, S., Preiser, P. R., and Yoon, H. S. (2013). Small
molecule Plasmodium FKBP35 inhibitor as a potential antimalaria agent. Sci.
Rep. 3, 2501. doi:10.1038/srep02501
Helbig, J. H., Lück, P. C., Steinert, M., Jacobs, E., and Witt, M. (2001). Immunolocal-
ization of the Mip protein of intracellularly and extracellularly grown Legionella
pneumophila. Lett. Appl. Microbiol. 32, 83–88. doi:10.1046/j.1472-765x.2001.
00861.x
Henderson, B., and Martin, A. C. R. (2014). Protein moonlighting: a new fac-
tor in biology and medicine. Biochem. Soc. Trans. 42, 1671–1678. doi:10.1042/
BST20140273
Hoffmann, A., Bukau, B., and Kramer, G. (2010). Structure and function of the
molecular chaperone trigger factor. Biochim. Biophys. Acta 1803, 650–661.
doi:10.1016/j.bbamcr.2010.01.017
Juli, C., Sippel, M., Jäger, J., Thiele, A., Weiwad, M., Schweimer, K., et al. (2011).
Pipecolic acid derivatives as small-molecule inhibitors of the Legionella MIP
protein. J. Med. Chem. 54, 277–283. doi:10.1021/jm101156y
Köhler, R., Fanghänel, J., König, B., Lüneberg, E., Frosch, M., Rahfeld, J.-U., et al.
(2003). Biochemical and functional analyses of the Mip protein: influence of
the N-terminal half and of peptidylprolyl isomerase activity on the virulence
of Legionella pneumophila. Infect. Immun. 71, 4389–4397. doi:10.1128/IAI.71.8.
4389-4397.2003
Lang, K., Schmid, F. X., and Fischer, G. (1987). Catalysis of protein folding by prolyl
isomerase. Nature 329, 268–270. doi:10.1038/329268a0
Leuzzi, R., Serino, L., Scarselli, M., Savino, S., Fontana, M. R., Monaci, E., et al.
(2005). Ng-MIP, a surface-exposed lipoprotein of Neisseria gonorrhoeae, has a
peptidyl-prolyl cis/trans isomerase (PPIase) activity and is involved in persis-
tence in macrophages. Mol. Microbiol. 58, 669–681. doi:10.1111/j.1365-2958.
2005.04859.x
Liu, J.,Albers,M. W.,Wandless,T. J.,Luan,S.,Alberg,D. G.,Belshaw,P. J., et al. (1992).
Inhibition of T cell signaling by immunophilin-ligand complexes correlates
with loss of calcineurin phosphatase activity. Biochemistry 31, 3896–3901.
doi:10.1021/bi00131a002
Lundemose, A. G., Kay, J. E., and Pearce, J. H. (1993). Chlamydia trachomatis Mip-
like protein has peptidyl-prolyl cis/trans isomerase activity that is inhibited by
FK506 and rapamycin and is implicated in initiation of chlamydial infection.
Mol. Microbiol. 7, 777–783. doi:10.1111/j.1365-2958.1993.tb01168.x
Mo,Y. Y., Cianciotto, N. P., and Mallavia, L. P. (1995). Molecular cloning of a Coxiella
burnetii gene encoding a macrophage infectivity potentiator (Mip) analogue.
Microbiology 141(Pt 11), 2861–2871. doi:10.1099/13500872-141-11-2861
Moro,A., Ruiz-Cabello, F., Fernández-Cano,A., Stock, R. P., and González,A. (1995).
Secretion by Trypanosoma cruzi of a peptidyl-prolyl cis-trans isomerase involved
in cell infection. EMBO J. 14, 2483–2490.
Norville, I. H., O’Shea, K., Sarkar-Tyson, M., Zheng, S., Titball, R. W.,Varani, G., et al.
(2011). The structure of a Burkholderia pseudomallei immunophilin-inhibitor
complex reveals new approaches to antimicrobial development. Biochem. J. 437,
413–422. doi:10.1042/BJ20110345
Rasch, J., Unal, C. M., and Steinert, M. (2014). Peptidylprolyl cis-trans isomerases of
Legionella pneumophila: virulence, moonlighting and novel therapeutic targets.
Biochem. Soc. Trans. 42, 1728–1733. doi:10.1042/BST20140202
Riboldi-Tunnicliffe, A., König, B., Jessen, S., Weiss, M. S., Rahfeld, J., Hacker, J., et al.
(2001). Crystal structure of Mip, a prolylisomerase from Legionella pneumophila.
Nat. Struct. Biol. 8, 779–783. doi:10.1038/nsb0901-779
Rockey, D. D., Chesebro, B. B., Heinzen, R. A., and Hackstadt, T. (1996). A
28 kDa major immunogen of Chlamydia psittaci shares identity with Mip
proteins of Legionella spp. and Chlamydia trachomatis-cloning and charac-
terization of the C. psittaci mip-like gene. Microbiology 142(Pt 4), 945–953.
doi:10.1099/00221287-142-4-945
Ünal, C., Schwedhelm, K. F., Thiele, A., Weiwad, M., Schweimer, K., Frese, F., et al.
(2011). Collagen IV-derived peptide binds hydrophobic cavity of Legionella
pneumophila Mip and interferes with bacterial epithelial transmigration. Cell.
Microbiol. 13, 1558–1572. doi:10.1111/j.1462-5822.2011.01641.x
Ünal, C. M., and Steinert, M. (2014). Microbial peptidyl-prolyl cis/trans isomerases
(PPIases): virulence factors and potential alternative drug targets. Microbiol. Mol.
Biol. Rev. 78, 544–571. doi:10.1128/MMBR.00015-14
Wagner, C., Khan, A. S., Kamphausen, T., Schmausser, B., Ünal, C., Lorenz, U., et al.
(2007). Collagen binding protein Mip enables Legionella pneumophila to trans-
migrate through a barrier of NCI-H292 lung epithelial cells and extracellular
matrix. Cell. Microbiol. 9, 450–462. doi:10.1111/j.1462-5822.2006.00802.x
Wintermeyer, E., Ludwig, B., Steinert, M., Schmidt, B., Fischer, G., and Hacker, J.
(1995). Influence of site specifically altered Mip proteins on intracellular survival
of Legionella pneumophila in eukaryotic cells. Infect. Immun. 63, 4576–4583.
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 19 December 2014; paper pending published: 06 February 2015; accepted: 15
March 2015; published online: 27 March 2015.
Citation: Rasch J, Theuerkorn M, Ünal C, Heinsohn N, Tran S, Fischer G, Weiwad
M and Steinert M (2015) Novel cycloheximide derivatives targeting the moonlight-
ing protein Mip exhibit specific antimicrobial activity against Legionella pneumophila.
Front. Bioeng. Biotechnol. 3:41. doi: 10.3389/fbioe.2015.00041
This article was submitted to Bioinformatics and Computational Biology, a section of
the journal Frontiers in Bioengineering and Biotechnology.
Copyright © 2015 Rasch, Theuerkorn, Ünal, Heinsohn, Tran, Fischer , Weiwad and
Steinert . This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
Frontiers in Bioengineering and Biotechnology | Bioinformatics and Computational Biology March 2015 | Volume 3 | Article 41 | 8
